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Objectives
To evaluate long-term safety and efficacy of tocilizumab
in treatment of children with systemic JIA.
Methods
Patients with systemic JIA fulfilled WHO/ILAR criteria
were enrolled in long-term extension study immediately
after completion of phase II and III trials of tocilizumab.
Tocilizumab was intravenously administered at a dose of
8 mg/kg every 2 weeks. Efficacy was assessed every 6 weeks
using ACR Pedi 30 Criteria for Improvement.
Results
Sixty seven patients (29 boys and 38 girls) were included
in this analysis. Median age was 8 years and median dis-
ease duration was 3.8 years. At the time of analysis, 9
patients had discontinued tocilizumab treatment, 4 due
to AEs, 4 due to development of anti-tocilizumab anti-
bodies and 1 due to lack of efficacy. Median duration of
tocilizumab treatment was 146 weeks. The most frequent
AEs were upper respiratory tract infections and gastroen-
teritis. The incidence rate of serious infections was 10.7
per 100 patient-years. No deaths, malignancies, or
autoimmune diseases were observed. ACR Pedi 30, 50
and 70 Improvement Criteria were achieved in 100%,
98% and 93% at Week 96. All patients were treated with
oral corticosteroids at the registration and 72% were able
to reduce corticosteroid dose by more than 50% at Week
96. Fourteen patients became steroid-free during the
study. 4 patients were in remission without tocilizumab
itself and any other medications.
Conclusion
The long-term extension study demonstrated sustained
clinical improvement and a favourable risk-benefit profile
for tocilizumab treatment in children with systemic JIA.
Even medication-off status will be expected.
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